Phase 3b STARDUST study data on crohn’s disease

Dr. Jan Wehkamp, M.D. Vice President and Gastroenterology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC, talks about data from the Phase 3b, STARDUST study, showing that two doses of STELARA® (ustekinumab) induced clinical remission in two-thirds of patients with Crohn’s Disease (CD).  STARDUST is the first study to compare a treat to target approach with standard of care in CD and using endoscopy to guide use of medication.

Jan Wehkamp, M.D. is Vice President and Gastroenterology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, he is responsible for driving scientific leadership in gastroenterology for many of Janssen’s active development programs including STELARA® (ustekinumab) and TREMFYA® (guselkumab) as well as many innovative compounds in early development. Prior to his role at Janssen, Jan served as a Heisenberg professor of medicine, teaching innate immunology in inflammation and infection at the University of Tübingen in Baden-Württemberg, Germany. In addition, he was the Chief Scientific Officer for Defensin Therapeutics, a Danish biopharmaceutical company he cofounded in 2013, that is focused on developing and commercializing products for diseases associated with dysregulation of the human microbiota. The company’s research is based on more than two decades expertise coming from Jan’s laboratory at the University of Tübingen. Prior to this, Jan worked as a Principal Investigator of Research in Gastroenterology and Pharmacology at the Dr. Margarete-Fischer-Bosch-Institute of Clinical Pharmacology in Germany. Jan has authored more than 120 publications and key presentations. He received his M.D. from University of Lübeck in Germany and completed his post-doctoral work in Immunology & Microbiology at the Cleveland Clinic in Ohio and University of California in Davis, California.